28 Results for "

Beta-blocker

" in MedChemExpress (MCE) Product Catalog:
Products (28)

28 Results for "Beta-blocker" in MCE Product Catalog:

Cat. No.: HY-17494R
CAS No.: 26839-75-8
Synonyms: (S)-L-714,465 (Standard); MK 950 free base (Standard)
Timolol (Standard) is the analytical standard of Timolol. This product is intended for research and analytical applications. Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .
loading...
    loading...
Cat. No.: HY-107155
CAS No.: 104970-08-3
β-Blocker B-24/76 is a beta adrenoceptor blocker. β-Blocker B-24/76 exhibits beta 1-adrenoceptor blocking and beta 2-adrenoceptor stimulating properties. β-Blocker B-24/76 can suppress the increased ornithine decarboxylase activity in hypertrophied hearts. β-Blocker B-24/76 can be used for the research of cardiovascular disease .
loading...
    loading...
Cat. No.: HY-122537AR
CAS No.: 68377-92-4
Arotinolol (Standard) is the analytical standard of Arotinolol. This product is intended for research and analytical applications. Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites . Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .
loading...
    loading...
Cat. No.: HY-W653969
CAS No.: 2514848-16-7
Arotinolol-d5 (hydrochloride) is deuterium labeled Arotinolol. Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites. Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .
loading...
    loading...
Cat. No.: HY-167681
CAS No.: 68020-77-9
Synonyms: Ro 12-4713
Target:  

Endogenous Metabolite

Research Areas:  

Cardiovascular Disease

Carprazidil (Ro 12-4713) is a potent vasodilator with activity in suppressing severe hypertension and mild heart failure. The use of carprazidil may lead to sodium retention and increased heart rate, requiring increased doses of diuretics or beta-blockers in some cases. Carprazidil and mecycline may both cause hirsutism, limiting their long-term use in women. Carprazidil did not cause adverse side effects on hematological parameters, liver, or kidney function .
loading...
    loading...
Cat. No.: HY-182611
CAS No.: 1637468-93-9
Target:  

TGF-β Receptor

Research Areas:  

Inflammation/Immunology Cancer

SRI-31277 is a thrombospondin 1 (TSP-1) inhibitor with a human target pIC50 of 8.28 nM and in vivo activity, and exhibits a very short plasma half-life with intravenous administration.SRI-31277 inhibits interaction between TSP-1 and the latency-associated peptide (LAP) of latent TGF-β, blocking TSP-1-mediated TGF-β activation.SRI-31277 can be used for the research of multiple myeloma and fibrotic conditions .
loading...
    loading...
Cat. No.: HY-187366
Target:  

PDGFR Apoptosis

Research Areas:  

Cancer

PDGFRβ-IN-1 is an orally active PDGFRβ inhibitor with an IC50 of 3.9 nM against human PDGFRβ. PDGFRβ-IN-1 selectively inhibits PDGFRβ, blocks its downstream signaling pathways, and promotes its degradation via a non-classical pathway. PDGFRβ-IN-1 inhibits cancer cell proliferation, migration and colony formation, and induces cancer cell apoptosis. PDGFRβ-IN-1 suppresses tumor growth in xenograft models. PDGFRβ-IN-1 can be used for the research of hepatocellular carcinoma .
loading...
    loading...
Cat. No.: HY-L145
930 compounds

The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.

Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs).

MCE offers a unique collection of 930 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.